Landmark Trial to Examine Cardiovascular Treatment in HIV Patients

Over the course of their careers, many clinicians have seen HIV/AIDS progress from extremely high short-term mortality to chronic, long-term disease management. As HIV patients are living longer with antiretroviral therapy, it is becoming clear that the virus increases risk of cardiovascular conditions.¹ The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) study will include 6,500 participants and be conducted at approximately 100 sites. Its purpose is to test whether use of a statin medication (pitavastatin) can lower event rates for cardiovascular events such as myocardial infarctions (MIs) and strokes in this immunocompromised population.

uchealth.com

Read the full article here.